Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADUS vs SGRY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADUS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

ADUS Overall Winner 6-Pillar Tally: ADUS 5 – 1 SGRY Matrix Metrics: ADUS 7 – 3 SGRY

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADUS vs SGRY
ADUS NASDAQ Head-to-Head Winner
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74
SGRY NASDAQ
Surgery Partners, Inc. Common Stock
Services-General Medical & Surgical Hospitals, Nec
$26.78
+0.34% 1D
Market Cap $3.5B
TTM Revenue $3.36B
Forward P/E N/M
Beta / 30D Vol 0.87β · 166% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 24.0 Flow 56.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.5% over 20 days), RSI 84
RSI-14: 84.4 · SMA20: $24.97 · SMA50: $18.56

6-Pillar Scorecard Institutional Category Breakdown (ADUS 5 – 1 SGRY)

Columns: Metric · ADUS · SGRY
1. Valuation Multiples ADUS
Forward P/E 16.1x N/M
Trailing P/E 20.1x N/M
PEG Ratio 1.05x 1.66x
EV / Revenue 1.5x 1.9x
2. Growth & Scale ADUS
Revenue Growth (YoY) +7.0% -0.8%
Earnings Growth (YoY) +24.2% +0.0%
TTM Revenue (USD) $1.50B $3.36B
Market Cap $2.3B $3.5B
3. Profitability & Quality ADUS
Gross Margin 32.3% 22.2%
Operating Margin 10.4% 13.2%
Net Profit Margin 7.4% -2.6%
Return on Equity (ROE) 10.0% 2.1%
4. Balance Sheet & Cash Flow ADUS
Cash Generation (TTM) $173M EBITDA $203M
Cash Flow Margin 11.5% EBITDA Mgn 6.0%
Net Cash / Leverage $64.64 Book/Sh · 10.0% ROE $2.96B Net Debt (1.99x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGRY
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 21.9% (16th %ile) 62.1% (34th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ADUS
OpEx & R&D Intensity 21.9% of Rev ($329M) 9.0% of Rev ($302M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADUS (7) vs SGRY (3)
Institutional Metric ADUS SGRY Criterion Row Edge
Market Capitalization
Scale
$2.3B $3.5B Larger Scale SGRY
Trailing P/E Ratio
Valuation
20.1x N/M Lower Multiple ADUS
Forward P/E Ratio
Valuation
16.1x N/M Lower Multiple ADUS
Revenue Growth (YoY)
Growth
+7.0% -0.8% Higher Growth ADUS
Operating Margin (TTM)
Profitability
10.4% 13.2% Higher Margin SGRY
Net Profit Margin
Profitability
7.4% -2.6% Higher Margin ADUS
Return on Equity (ROE)
Capital Efficiency
10.0% 2.1% Higher ROE ADUS
52-Week Range Position
Momentum
79% ($88–$132) 97% ($11–$27) Stronger Trend SGRY
Beta / 30D Volatility
Risk Regime
-0.07β · 21% Vol 0.87β · 166% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$1.50B $3.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 22.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.05x PEG · 1.5x EV/Rev 1.66x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$173M EBITDA ($64.64 Book/Sh · 10.0% ROE) $203M ($2.96B Net Debt (1.99x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGRY +68.57 pp
ADUS: -0.14% · SGRY: +68.43%
3M Horizon SGRY +90.58 pp
ADUS: +1.39% · SGRY: +91.97%
6M Horizon SGRY +67.63 pp
ADUS: +32.22% · SGRY: +99.85%
1Y Horizon SGRY +58.07 pp
ADUS: +12.39% · SGRY: +70.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs SGRY. Trailing 12-month operating profitability (ADUS 10.4% vs SGRY 13.2%) and valuation multiples (ADUS 16.1x vs SGRY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x
SGRY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.36B
Gross Margin22.2%
Op. Margin13.2%
ROE / Fwd P/E2.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGRY SURGE
5d in phase · OBV NEUTRAL
Current IV 62.1%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGRY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published
SGRY Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment 9.0% of Rev ($302M)
90D Engineering Disclosures 0 Published

Investor FAQ ADUS vs SGRY Key Questions & Quantitative Answers

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Technically, ADUS sits in a Markup phase (RSI 51.6, UNCLASSIFIED options structure) and SGRY sits in a Markup phase (RSI 84.4, SURGE options structure).

ADUS leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $3.36B for SGRY. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.

ADUS screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus SGRY (2.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.